| Smart polymersomes and hydrogels from polypeptide-based polymer systems through α-amino acid N-carboxyanhydride ring-opening polymerization. From chemistry to biomedical … E Liarou, S Varlas, D Skoulas, C Tsimblouli, E Sereti, K Dimas, H Iatrou Progress in Polymer Science 83, 28-78, 2018 | 86 | 2018 |
| A promising natural product, pristimerin, results in cytotoxicity against breast cancer stem cells in vitro and xenografts in vivo through apoptosis and an incomplete autopaghy … B Cevatemre, M Erkısa, N Aztopal, D Karakas, P Alper, C Tsimplouli, ... Pharmacological Research 129, 500-514, 2018 | 74 | 2018 |
| Self-healing pH-and enzyme stimuli-responsive hydrogels for targeted delivery of gemcitabine to treat pancreatic cancer P Bilalis, D Skoulas, A Karatzas, J Marakis, A Stamogiannos, C Tsimblouli, ... Biomacromolecules 19 (9), 3840-3852, 2018 | 64 | 2018 |
| Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devastating cancer? E Sereti, T Karagianellou, I Kotsoni, D Magouliotis, K Kamposioras, ... Journal of proteomics 188, 107-118, 2018 | 36 | 2018 |
| RETRACTED ARTICLE: Annonacin promotes selective cancer cell death via NKA-dependent and SERCA-dependent pathways A Yiallouris, I Patrikios, EO Johnson, E Sereti, K Dimas, C De Ford, ... Cell Death & Disease 9 (7), 764, 2018 | 31 | 2018 |
| Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma Z Milošević, J Banković, J Dinić, C Tsimplouli, E Sereti, M Dragoj, ... Cellular oncology 41, 409-426, 2018 | 28 | 2018 |
| Study of the relationship between sigma receptor expression levels and some common sigma ligand activity in cancer using human cancer cell lines of the nci-60 cell line panel E Sereti, C Tsimplouli, E Kalaitsidou, N Sakellaridis, K Dimas Biomedicines 9 (1), 38, 2021 | 15 | 2021 |
| Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors M Dragoj, J Bankovic, E Sereti, SJ Stojanov, K Dimas, M Pesic, ... Investigational New Drugs 35 (6), 718-732, 2017 | 14 | 2017 |
| mTORC2 deploys the mRNA binding protein IGF2BP1 to regulate c-MYC expression and promote cell survival A Lambrianidou, E Sereti, K Soupsana, C Komini, K Dimas, T Trangas Cellular Signalling 80, 109912, 2021 | 12 | 2021 |
| Chimeric stimuli-responsive liposomes as nanocarriers for the delivery of the anti-glioma agent TRAM-34 N Naziris, N Pippa, E Sereti, V Chrysostomou, M Kędzierska, J Kajdanek, ... International Journal of Molecular Sciences 22 (12), 6271, 2021 | 9 | 2021 |
| Pancreatic cancer organoids: an emerging platform for precision medicine? E Sereti, I Papapostolou, K Dimas Biomedicines 11 (3), 890, 2023 | 8 | 2023 |
| P90 ribosomal S6 kinases: A bona fide target for novel targeted anticancer therapies? F Koutsougianni, D Alexopoulou, A Uvez, A Lamprianidou, E Sereti, ... Biochemical Pharmacology 210, 115488, 2023 | 5 | 2023 |
| Increased expression of the mitochondrial glucocorticoid receptor enhances tumor aggressiveness in a mouse xenograft model AG Karra, I Tsialtas, FD Kalousi, A Georgantopoulos, E Sereti, K Dimas, ... International journal of molecular sciences 24 (4), 3740, 2023 | 4 | 2023 |
| Combination of the PARP inhibitor olaparib with a novel vascular disrupting agent, NOV202, reduces tumor growth in BRCA1/2 mutated prostate cancer xenografts E Sereti, S Evans-Axelsson, R Hellsten, S Rehnmark, M Högberg, ... European Urology Open Science 56, S39, 2023 | | 2023 |
| Combination of the PARP inhibitor olaparib with the vascular disrupting agent NOV202 reduces tumor growth in BRCA1/2 mutated prostate cancer xenografts AS Bjartell, E Sereti, SE Axelsson European Urology Open Science 48, S22, 2023 | | 2023 |
| Combination of PARP inhibitor olaparib with the vascular disrupting agent NOV202 reduces tumor growth in BRCA1/2 mutated prostate cancer xenografts E Sereti, S Rehnmark, M Högberg, A Bjartell European Urology Open Science 44, S224, 2022 | | 2022 |
| Annonacin promotes selective cancer cell death via NKA-dependent and SERCA-dependent pathways (July, 10.1038/s41419-018-0772-x, 2018)(Retraction of 10.1038/S41419-018-0772-X, 2018) A Yiallouris, I Patrikios, EO Johnson, E Sereti, K Dimas, C De Ford, ... CELL DEATH & DISEASE 13 (9), 2022 | | 2022 |
| Retraction Note: Annonacin promotes selective cancer cell death via NKA-dependent and SERCA-dependent pathways A Yiallouris, I Patrikios, EO Johnson, E Sereti, K Dimas, C De Ford, ... Cell Death & Disease 13 (9), 2022 | | 2022 |
| Pharmacological characterization of a novel lipid-rich breast cancer patient-derived xenograft I Papapostolou, E Sereti, F Koutsougianni, E Bouloutsou, V Konteles, ... EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 78 (SUPPL 1), S6-S6, 2022 | | 2022 |
| A novel vascular disrupting agent (NOV202) increases the anticancer efficacy of the PARP inhibitor olaparib in prostate cancer cells with BRCA1/2 mutations E Sereti, S Evans-Axelsson, S Rehnmark, M Hogberg, A Bjartell EUROPEAN UROLOGY 79, S608-S608, 2021 | | 2021 |
Konstantinos dimasLaboratory of Pharmacology, Faculty of Medicine, University of Thessaly, Greec在 med.uth.gr 的电子邮件经过验证
